Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 7/20 | 0.64 |
| ▸ | DRD4 | P21917 | 3/20 | 0.60 |
| ▸ | DRD2 | P14416 | 1/20 | 0.60 |
| ▸ | DRD3 | P35462 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.58 |
| ▸ | KRAS | P01116 | 1/20 | 0.58 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7368538 | 0.89 | SLC6A5 (0.61) | SIGMAR1KMT2AALDH1A1POLB | |
| SCHEMBL7364841 | 0.89 | SLC6A5 (0.61) | SIGMAR1KMT2AALDH1A1POLB | |
| SCHEMBL4846139 | 0.86 | SIGMAR1 (0.60) | SIGMAR1DRD4DRD2DRD3KMT2A | |
| SCHEMBL4846164 | 0.86 | SIGMAR1 (0.60) | SIGMAR1DRD4DRD2DRD3KMT2A | |
| SCHEMBL6207514 | 0.86 | SIGMAR1 (0.60) | SIGMAR1DRD4DRD2DRD3KMT2A | |
| SCHEMBL28750874 | 0.86 | KDM4E (0.55) | KMT2AKRASSOS1 | |
| SCHEMBL28750876 | 0.86 | KDM4E (0.55) | KMT2AKRASSOS1 | |
| SCHEMBL4848461 | 0.86 | SIGMAR1 (0.65) | SIGMAR1DRD4DRD2DRD3KMT2A | |
| SCHEMBL2317579 | 0.85 | SIGMAR1 (0.64) | SIGMAR1DRD4DRD2DRD3KMT2A | |
| SCHEMBL6166506 | 0.84 | TDP1 (0.61) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2009-06-25 | — | — | US | disclosed |
| US-7498325-B2 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | KARL THOMAS GMBH (DE) | 2009-03-03 | — | — | US | disclosed |
| EP-1440976-B1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | BOEHRINGER INGELHEIM PHARMA (DE) | 2008-07-23 | — | — | EP | disclosed |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | DR. KARL THOMAE GMBH (DE) | 2004-10-28 | — | — | US | disclosed |
| EP-0927192-B1 | MODIFIED AMINOACIDS, PHARMACEUTICALS CONTAINING THESE COMPOUNDS AND METHOD FOR THEIR PRODUCTION | BOEHRINGER INGELHEIM PHARMA (DE) | 2004-05-12 | — | — | EP | disclosed |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2003-04-10 | — | — | US | disclosed |
| US-6344449-B1 | HEADACHE AND MORPHINE DEPENDENCE | DR. KARL THOMAE GMBH (DE) | 2002-02-05 | — | — | US | disclosed |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | RUDOLF KLAUS (DE) | 2001-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163480-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, CHRM1, SRMS | SIGMAR1 377/4885DRD4 139/4885DRD2 187/4885 |
| US-20040214819-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | SIGMAR1 429/4885DRD4 125/4885DRD2 198/4885 |
| US-20030069231-A1 | Modified aminoacids, pharmaceuticals containing these compounds and method for their production | SLC1A5, NEFM, SRMS | SIGMAR1 421/4885DRD4 86/4885DRD2 130/4885 |
| US-20010036946-A1 | Modified amino acids, pharmaceuticals containing these compounds and method for their production | PTMS, SRMS, OPRM1 | SIGMAR1 429/4885DRD4 125/4885DRD2 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.